Home › Free Stock Grades › RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Grade
RYTM · Healthcare
C
Market Cap
$6.8B
P/E Ratio
—
Revenue Growth (YoY)
+45.8%
Net Margin
-103.6%
Return on Equity
—
Dividend Yield
None
About Rhythm Pharmaceuticals, Inc.'s fundamentals
Rhythm Pharmaceuticals is a biotechnology company with a market capitalization of $6.8 billion that is experiencing strong revenue growth at 45.8% year-over-year, indicating expanding commercial operations. However, the company is currently unprofitable, with a net margin of -103.6%, meaning it is spending more than twice its revenue on operating expenses and reported a net loss in its latest annual statement. The company does not pay a dividend, which is typical for early-stage biotech firms that prioritize reinvesting capital into research and development.